Alcon Inc. logo

Alcon Inc. (ALC)

Market Closed
2 Mar, 20:00
NYSE NYSE
$
84. 68
-2.5
-2.87%
$
42.49B Market Cap
- P/E Ratio
1.06% Div Yield
2,299,496 Volume
- Eps
$ 87.18
Previous Close
Day Range
83.67 85.12
Year Range
71.55 99.2
Want to track ALC and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
ALC earnings report is expected in 77 days (19 May 2026)
Harding Loevner International Equity ADR Q3 2025 Portfolio Update

Harding Loevner International Equity ADR Q3 2025 Portfolio Update

The International Equity ADR composite rose 3.0% gross of fees in the second quarter, behind the 7.0% gain of the MSCI ACWI ex US Index. In Communication Services, Tencent delivered a second consecutive quarter of double-digit revenue and profit growth. Japan was the largest detractor, with Chugai and Sysmex weighing on results.

Seekingalpha | 4 months ago
Here's Why Alcon (ALC) is a Strong Momentum Stock

Here's Why Alcon (ALC) is a Strong Momentum Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks | 4 months ago
Alcon's UNITY VCS Shows Superior Efficiency in Studies, Stock Up

Alcon's UNITY VCS Shows Superior Efficiency in Studies, Stock Up

ALC's UNITY VCS shows faster, more efficient cataract and vitreoretinal surgery results, lifting shares after study presentations.

Zacks | 5 months ago
Alcon's Q2 Earnings Beat Estimates, Revenues Miss, Stock Plunges

Alcon's Q2 Earnings Beat Estimates, Revenues Miss, Stock Plunges

ALC's Q2 earnings top estimates but revenues fall short, sending shares down more than 10% as margins tightened and 2025 sales outlook narrowed.

Zacks | 6 months ago
Alcon Inc. (ALC) Q2 2025 Earnings Call Transcript

Alcon Inc. (ALC) Q2 2025 Earnings Call Transcript

Alcon Inc. (NYSE:ALC ) Q2 2025 Earnings Conference Call August 20, 2025 8:00 AM ET Call Participants Daniel Cravens - Vice President of Investor Relations David J. Endicott - CEO & Director Timothy C.

Seekingalpha | 6 months ago
Alcon Shares Fall After Guidance Trim on U.S. Trade Tariff Hit

Alcon Shares Fall After Guidance Trim on U.S. Trade Tariff Hit

The company said it expects a $100 million hit from tariffs this year.

Wsj | 6 months ago
Compared to Estimates, Alcon (ALC) Q2 Earnings: A Look at Key Metrics

Compared to Estimates, Alcon (ALC) Q2 Earnings: A Look at Key Metrics

The headline numbers for Alcon (ALC) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Zacks | 6 months ago
Stay Ahead of the Game With Alcon (ALC) Q2 Earnings: Wall Street's Insights on Key Metrics

Stay Ahead of the Game With Alcon (ALC) Q2 Earnings: Wall Street's Insights on Key Metrics

Get a deeper insight into the potential performance of Alcon (ALC) for the quarter ended June 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.

Zacks | 6 months ago
Alcon Stock Gains Following UNITY VCS' Approval in Canada

Alcon Stock Gains Following UNITY VCS' Approval in Canada

ALC's UNITY VCS gets Canada's approval, advancing surgical precision with faster, more efficient technology.

Zacks | 7 months ago
Is it Apt to Retain Alcon Stock in Your Portfolio for Now?

Is it Apt to Retain Alcon Stock in Your Portfolio for Now?

ALC stays on investors' radar due to its Vision Care arm's performance and contributions from new products despite macro risks and stiff competition.

Zacks | 8 months ago
Alcon Stock Rises Following the FDA Approval of TRYPTYR

Alcon Stock Rises Following the FDA Approval of TRYPTYR

FDA approves ALC's TRYPTYR, a new dry eye treatment with rapid tear production. The approval is supported by strong Phase 3 trial results.

Zacks | 9 months ago
US FDA approves Alcon's new dry-eye drug

US FDA approves Alcon's new dry-eye drug

Eye-care drugmaker Alcon said on Wednesday that the U.S. Food and Drug Administration has approved its treatment for dry eye disease (DED).

Reuters | 9 months ago
Loading...
Load More